APO RESEARCH · REPORT
5 Nucleotidase
5 Nucleotidase refers to research coverage of agents targeting 5-prime nucleotidase/CD73 within the selected edition.
Product & engineering
Understand the product.
The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.
What turns activity into demand
Distinguish equipment procurement, recurring materials and any related service within the selected study. Research use, educational use and clinical use have different acceptance requirements and should not be treated as one demand measure.
The commercial boundary
Separate research materials, devices and services within the selected edition. Approvals, labelled use and clinical acceptance need their own evidence; no medical suitability follows from this illustration.
Which supplied scope and interfaces define 5 Nucleotidase?
The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.
Technical reading
Selected research
Industry Research
5 Nucleotidase Industry Research Report 2026
Market perspective
The global 5 Nucleotidase market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for 5 Nucleotidase is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for 5 Nucleotidase is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of 5 Nucleotidase include Bristol-Myers Squibb Co, Corvus Pharmaceuticals Inc, Innate Pharma SA, MedImmune LLC and Surface Oncology Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global 5 Nucleotidase market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
5 Nucleotidase Market by Company
Bristol-Myers Squibb Co
Corvus Pharmaceuticals Inc
Innate Pharma SA
MedImmune LLC
Surface Oncology Inc
5 Nucleotidase Segment by Type
IPH-53
CPX-006
BMS-986179
AB-680
Others
5 Nucleotidase Segment by Application
Colorectal Cancer
Fallopian Tube Cancer
Gastric Cancer
Metastatic Colorectal Cancer
Others
5 Nucleotidase Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 5 Nucleotidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 5 Nucleotidase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 5 Nucleotidase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of 5 Nucleotidase manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of 5 Nucleotidase by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of 5 Nucleotidase in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IPH-53
- CPX-006
- BMS-986179
- AB-680
- Others
Applications
- Colorectal Cancer
- Fallopian Tube Cancer
- Gastric Cancer
- Metastatic Colorectal Cancer
- Others
Companies covered
- Bristol-Myers Squibb Co
- Corvus Pharmaceuticals Inc
- Innate Pharma SA
- MedImmune LLC
- Surface Oncology Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global 5 Nucleotidase Market Size (2021-2032)
- 2.2.2 Global 5 Nucleotidase Sales (2021-2032)
- 2.2.3 Global 5 Nucleotidase Market Average Price (2021-2032)
- 2.3 5 Nucleotidase by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 IPH-53
- 2.3.3 CPX-006
- 2.3.4 BMS-986179
- 2.3.5 AB-680
- 2.3.6 Others
- 2.4 5 Nucleotidase by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Colorectal Cancer
- 2.4.3 Fallopian Tube Cancer
- 2.4.4 Gastric Cancer
- 2.4.5 Metastatic Colorectal Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global 5 Nucleotidase Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global 5 Nucleotidase Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global 5 Nucleotidase Revenue of Manufacturers (2021-2026)
- 3.4 Global 5 Nucleotidase Average Price by Manufacturers (2021-2026)
- 3.5 Global 5 Nucleotidase Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of 5 Nucleotidase, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of 5 Nucleotidase, Product Type & Application
- 3.8 Global Manufacturers of 5 Nucleotidase, Established Date
- 3.9 Global 5 Nucleotidase Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb Co
- 4.1.1 Bristol-Myers Squibb Co Company Information
- 4.1.2 Bristol-Myers Squibb Co Business Overview
- 4.1.3 Bristol-Myers Squibb Co 5 Nucleotidase Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Co 5 Nucleotidase Product Portfolio
- 4.1.5 Bristol-Myers Squibb Co Recent Developments
- 4.2 Corvus Pharmaceuticals Inc
- 4.2.1 Corvus Pharmaceuticals Inc Company Information
- 4.2.2 Corvus Pharmaceuticals Inc Business Overview
- 4.2.3 Corvus Pharmaceuticals Inc 5 Nucleotidase Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Corvus Pharmaceuticals Inc 5 Nucleotidase Product Portfolio
- 4.2.5 Corvus Pharmaceuticals Inc Recent Developments
- 4.3 Innate Pharma SA
- 4.3.1 Innate Pharma SA Company Information
- 4.3.2 Innate Pharma SA Business Overview
- 4.3.3 Innate Pharma SA 5 Nucleotidase Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Innate Pharma SA 5 Nucleotidase Product Portfolio
- 4.3.5 Innate Pharma SA Recent Developments
- 4.4 MedImmune LLC
- 4.4.1 MedImmune LLC Company Information
- 4.4.2 MedImmune LLC Business Overview
- 4.4.3 MedImmune LLC 5 Nucleotidase Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MedImmune LLC 5 Nucleotidase Product Portfolio
- 4.4.5 MedImmune LLC Recent Developments
- 4.5 Surface Oncology Inc
- 4.5.1 Surface Oncology Inc Company Information
- 4.5.2 Surface Oncology Inc Business Overview
- 4.5.3 Surface Oncology Inc 5 Nucleotidase Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Surface Oncology Inc 5 Nucleotidase Product Portfolio
- 4.5.5 Surface Oncology Inc Recent Developments
5 Global 5 Nucleotidase Market Scenario by Region
- 5.1 Global 5 Nucleotidase Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global 5 Nucleotidase Sales by Region: 2021-2032
- 5.2.1 Global 5 Nucleotidase Sales by Region: 2021-2026
- 5.2.2 Global 5 Nucleotidase Sales by Region: 2027-2032
- 5.3 Global 5 Nucleotidase Revenue by Region: 2021-2032
- 5.3.1 Global 5 Nucleotidase Revenue by Region: 2021-2026
- 5.3.2 Global 5 Nucleotidase Revenue by Region: 2027-2032
- 5.4 North America 5 Nucleotidase Market Facts & Figures by Country
- 5.4.1 North America 5 Nucleotidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America 5 Nucleotidase Sales by Country (2021-2032)
- 5.4.3 North America 5 Nucleotidase Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe 5 Nucleotidase Market Facts & Figures by Country
- 5.5.1 Europe 5 Nucleotidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe 5 Nucleotidase Sales by Country (2021-2032)
- 5.5.3 Europe 5 Nucleotidase Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific 5 Nucleotidase Market Facts & Figures by Country
- 5.6.1 Asia Pacific 5 Nucleotidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific 5 Nucleotidase Sales by Country (2021-2032)
- 5.6.3 Asia Pacific 5 Nucleotidase Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America 5 Nucleotidase Market Facts & Figures by Country
- 5.7.1 South America 5 Nucleotidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America 5 Nucleotidase Sales by Country (2021-2032)
- 5.7.3 South America 5 Nucleotidase Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa 5 Nucleotidase Market Facts & Figures by Country
- 5.8.1 Middle East and Africa 5 Nucleotidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa 5 Nucleotidase Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa 5 Nucleotidase Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global 5 Nucleotidase Sales by Type (2021-2032)
- 6.1.1 Global 5 Nucleotidase Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global 5 Nucleotidase Sales Market Share by Type (2021-2032)
- 6.2 Global 5 Nucleotidase Revenue by Type (2021-2032)
- 6.2.1 Global 5 Nucleotidase Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global 5 Nucleotidase Revenue Market Share by Type (2021-2032)
- 6.3 Global 5 Nucleotidase Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global 5 Nucleotidase Sales by Application (2021-2032)
- 7.1.1 Global 5 Nucleotidase Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global 5 Nucleotidase Sales Market Share by Application (2021-2032)
- 7.2 Global 5 Nucleotidase Revenue by Application (2021-2032)
- 7.2.1 Global 5 Nucleotidase Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global 5 Nucleotidase Revenue Market Share by Application (2021-2032)
- 7.3 Global 5 Nucleotidase Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 5 Nucleotidase Value Chain Analysis
- 8.1.1 5 Nucleotidase Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 5 Nucleotidase Production Mode & Process
- 8.2 5 Nucleotidase Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 5 Nucleotidase Distributors
- 8.2.3 5 Nucleotidase Customers
9 Global 5 Nucleotidase Analyzing Market Dynamics
- 9.1 5 Nucleotidase Industry Trends
- 9.2 5 Nucleotidase Industry Drivers
- 9.3 5 Nucleotidase Industry Opportunities and Challenges
- 9.4 5 Nucleotidase Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst